search
Back to results

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

Primary Purpose

Gastric Cancer, HER2 Overexpressing Gastric Carcinoma

Status
Recruiting
Phase
Phase 3
Locations
China
Study Type
Interventional
Intervention
RC48-ADC
Paclitaxel injection
Irinotecan Hydrochloride Injection
Apatinib Mesylate Tablets
Sponsored by
RemeGen Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gastric Cancer focused on measuring RC48-ADC, HER2 overexpression, Gastric cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Voluntary agreement to provide written informed consent.
  • Male or female, Age ≥ 18 years.
  • Predicted survival ≥ 12 weeks.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
  • All female subjects will be considered to be of child-bearing potential unless they are postmenopausal, or have been sterilized surgically.Female subjects of child-bearing potential must agree to use two forms of highly effective contraception. Male subjects and their female partner who are of child-bearing potential must agree to use two forms of highly effective contraception.
  • Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol.
  • Adequate organ function.
  • All subjects must have inoperable, advanced or metastatic gastric or or gastroesophageal adenocarcinoma
  • Have had progression or intolerance following receipt of at least two systemic chemotherapy for advanced or metastatic disease.
  • The HER2 IHC test result is IHC 2+ or IHC 3+, the subject's previous test results (confirmed by the investigator) or the research center's test results are acceptable; the subject can provide the Specimen of primary or metastatic tumor for HER2 review/judgment.
  • HER2 classic positive (definition: IHC3+ or IHC2+FISH+) and patients who have previously failed standard treatment
  • According to the RECIST 1.1 standard, there is at least one measurable lesion.

Exclusion Criteria:

  • Known hypersensitivity to Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection.
  • History of receiving any anti-cancer drug/biologic treatment within 4 weeks prior to trial treatment.
  • History of major surgery within 4 weeks of planned start of trial treatment.
  • Has received a live virus vaccine within 4 weeks of planned start of trial treatment.
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
  • History of other malignancy within the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or cancers with a similar curative outcome as those mentioned above.
  • Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.

Sites / Locations

  • Beijing Cancer HospitalRecruiting
  • Affiliated Hospital of Hebei UniversityRecruiting
  • China-Japan Friendship HospitalRecruiting
  • Luhe Hospital Affiliated to Capital Medical UniversityRecruiting
  • Peking University People's HospitalRecruiting
  • Jilin Provincial Tumor HospitalRecruiting
  • Xiangya Hospital of Central South UniversityRecruiting
  • Affiliated Hospital of Chengde Medical CollegeRecruiting
  • Three Gorges Hospital Affiliated to Chongqing UniversityRecruiting
  • Fujian Cancer HospitalRecruiting
  • Guangdong Provincial People's HospitalRecruiting
  • Southern Hospital of Southern Medical UniversityRecruiting
  • The First Affiliated Hospital of Sun Yat-sen UniversityRecruiting
  • The Sixth Affiliated Hospital of Sun Yat-sen UniversityRecruiting
  • First Affiliated Hospital of Zhejiang University School of MedicineRecruiting
  • Second Affiliated Hospital of Zhejiang University School of MedicineRecruiting
  • Zhejiang Cancer HospitalRecruiting
  • The Affiliated Tumor Hospital of Harbin Medical UniversityRecruiting
  • Anhui Cancer HospitalRecruiting
  • Anhui Provincial HospitalRecruiting
  • Jinan Central HospitalRecruiting
  • Shandong Cancer HospitalRecruiting
  • Affiliated Hospital of Jining Medical CollegeRecruiting
  • The First People's Hospital of Jining CityRecruiting
  • Lanzhou University Second HospitalRecruiting
  • Linyi Tumor HospitalRecruiting
  • Drum Tower Hospital Affiliated to Nanjing University School of MedicineRecruiting
  • Jiangsu Cancer HospitalRecruiting
  • The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital)Recruiting
  • Qingdao University HospitalRecruiting
  • Ruijin Hospital Affiliated to Shanghai Jiaotong University School of MedicineRecruiting
  • Shanghai Changhai HospitalRecruiting
  • Zhongshan Hospital Affiliated to Fudan UniversityRecruiting
  • Cancer Hospital Affiliated to Shantou University Medical CollegeRecruiting
  • Liaoning Cancer HospitalRecruiting
  • Shenzhen People's HospitalRecruiting
  • The First Affiliated Hospital of Soochow UniversityRecruiting
  • Shanxi Cancer HospitalRecruiting
  • Tianjin Cancer HospitalRecruiting
  • Weifang People's HospitalRecruiting
  • Weihai Municipal HospitalRecruiting
  • Huazhong University of Science Tongji Hospital, Tongji Medical CollegeRecruiting
  • The First Affiliated Hospital of Xi'an Jiaotong UniversityRecruiting
  • The First Affiliated Hospital of Xiamen UniversityRecruiting
  • Affiliated Hospital of Qinghai UniversityRecruiting
  • Qinghai Provincial People's HospitalRecruiting
  • The First Affiliated Hospital of Xinxiang Medical CollegeRecruiting
  • Affiliated Hospital of Xuzhou Medical UniversityRecruiting
  • Xuzhou Central HospitalRecruiting
  • Subei People's Hospital of Jiangsu ProvinceRecruiting
  • Yantai Yuhuangding HospitalRecruiting
  • Henan Cancer HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

RC48-ADC

Physician's Choice

Arm Description

Participants will receive RC48-ADC every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).

Participants will receive physician choosed chemotherapy from the following options: Paclitaxel Injection or Irinotecan Hydrochloride Injection or Apatinib Mesylate Tablets oral.

Outcomes

Primary Outcome Measures

Overall survival (OS)
Overall survival (OS) refers to the time from the date of randomization to the date of death of the subject.

Secondary Outcome Measures

Progression-free survival (PFS), evaluated by the investigator
Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher's evaluation of disease progression or death (calculated by the event that occurred first). The disease progression will be evaluated by the researchers according to the RECIST 1.1 standard.
Objective remission rate (ORR)
The objective response rate will be mainly analyzed by the independent efficacy evaluation committee according to the RECIST 1.1 standard tumor evaluation (the evaluation by the investigator will also be performed).
Duration of relief (DOR)
DOR is defined as the time from the first documented objective response (CR or PR) to the first documented disease progression or death
Disease control rate (DCR)
Disease control rate (DCR) is defined as cases where objective remission (assessed as complete remission or partial remission according to RECIST 1.1 standard) or stable disease during the study.
Tumor progression time (TTP)
Time to disease progression (TTP) refers to the time from the random date to the first disease progression (calculated by the event that occurred first). Disease progression will be evaluated by the investigator according to the RECIST 1.1 standard (investigator and Independent Review Committee(IRC) evaluation).

Full Information

First Posted
January 15, 2021
Last Updated
January 6, 2022
Sponsor
RemeGen Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT04714190
Brief Title
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
Official Title
Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of RC48-ADC for the Treatment of Locally Advanced or Metastatic Gastric Cancer With HER2-overexpression
Study Type
Interventional

2. Study Status

Record Verification Date
September 2021
Overall Recruitment Status
Recruiting
Study Start Date
March 24, 2021 (Actual)
Primary Completion Date
July 1, 2022 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
RemeGen Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a Phase III, randomized, multicenter, open-label clinical trial designed to compare RC48-ADC to physician choice standard treatment in participants with human epidermal growth factor receptor 2 (HER2)-overexpression locally advanced or metastatic gastric cancer.
Detailed Description
This study is a phase III multi-center, randomized, open-label, parallel control study to evaluate the efficacy and safety of recombinant humanized anti-HER2 monoclonal antibody-Monomethyl auristatin E (MMAE) conjugate for the treatment of HER2-overexpression locally advanced or metastatic gastric cancer. The HER2-overexpression is defined as: the HER2 IHC 3+ or 2+, regardless of FISH status.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastric Cancer, HER2 Overexpressing Gastric Carcinoma
Keywords
RC48-ADC, HER2 overexpression, Gastric cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
351 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
RC48-ADC
Arm Type
Experimental
Arm Description
Participants will receive RC48-ADC every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
Arm Title
Physician's Choice
Arm Type
Active Comparator
Arm Description
Participants will receive physician choosed chemotherapy from the following options: Paclitaxel Injection or Irinotecan Hydrochloride Injection or Apatinib Mesylate Tablets oral.
Intervention Type
Drug
Intervention Name(s)
RC48-ADC
Other Intervention Name(s)
Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection
Intervention Description
2.5 mg/kg IV every 2 weeks
Intervention Type
Drug
Intervention Name(s)
Paclitaxel injection
Other Intervention Name(s)
Taxol
Intervention Description
Administered according to label, as one option for Physician's Choice (determined before randomization)
Intervention Type
Drug
Intervention Name(s)
Irinotecan Hydrochloride Injection
Other Intervention Name(s)
CAMPTO
Intervention Description
Administered according to label, as one option for Physician's Choice (determined before randomization)
Intervention Type
Drug
Intervention Name(s)
Apatinib Mesylate Tablets
Other Intervention Name(s)
Aitan
Intervention Description
Administered according to label, as one option for Physician's Choice (determined before randomization)
Primary Outcome Measure Information:
Title
Overall survival (OS)
Description
Overall survival (OS) refers to the time from the date of randomization to the date of death of the subject.
Time Frame
within approximately 3 years
Secondary Outcome Measure Information:
Title
Progression-free survival (PFS), evaluated by the investigator
Description
Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher's evaluation of disease progression or death (calculated by the event that occurred first). The disease progression will be evaluated by the researchers according to the RECIST 1.1 standard.
Time Frame
within approximately 3 years
Title
Objective remission rate (ORR)
Description
The objective response rate will be mainly analyzed by the independent efficacy evaluation committee according to the RECIST 1.1 standard tumor evaluation (the evaluation by the investigator will also be performed).
Time Frame
within approximately 3 years
Title
Duration of relief (DOR)
Description
DOR is defined as the time from the first documented objective response (CR or PR) to the first documented disease progression or death
Time Frame
within approximately 3 years
Title
Disease control rate (DCR)
Description
Disease control rate (DCR) is defined as cases where objective remission (assessed as complete remission or partial remission according to RECIST 1.1 standard) or stable disease during the study.
Time Frame
within approximately 3 years
Title
Tumor progression time (TTP)
Description
Time to disease progression (TTP) refers to the time from the random date to the first disease progression (calculated by the event that occurred first). Disease progression will be evaluated by the investigator according to the RECIST 1.1 standard (investigator and Independent Review Committee(IRC) evaluation).
Time Frame
within approximately 3 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Voluntary agreement to provide written informed consent. Male or female, Age ≥ 18 years. Predicted survival ≥ 12 weeks. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. All female subjects will be considered to be of child-bearing potential unless they are postmenopausal, or have been sterilized surgically.Female subjects of child-bearing potential must agree to use two forms of highly effective contraception. Male subjects and their female partner who are of child-bearing potential must agree to use two forms of highly effective contraception. Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol. Adequate organ function. All subjects must have inoperable, advanced or metastatic gastric or or gastroesophageal adenocarcinoma Have had progression or intolerance following receipt of at least two systemic chemotherapy for advanced or metastatic disease. The HER2 IHC test result is IHC 2+ or IHC 3+, the subject's previous test results (confirmed by the investigator) or the research center's test results are acceptable; the subject can provide the Specimen of primary or metastatic tumor for HER2 review/judgment. HER2 classic positive (definition: IHC3+ or IHC2+FISH+) and patients who have previously failed standard treatment According to the RECIST 1.1 standard, there is at least one measurable lesion. Exclusion Criteria: Known hypersensitivity to Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection. History of receiving any anti-cancer drug/biologic treatment within 4 weeks prior to trial treatment. History of major surgery within 4 weeks of planned start of trial treatment. Has received a live virus vaccine within 4 weeks of planned start of trial treatment. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. History of other malignancy within the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or cancers with a similar curative outcome as those mentioned above. Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jianmin Fang, PhD
Phone
010-58075561
Email
jianminfang@hotmail.com
Facility Information:
Facility Name
Beijing Cancer Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100142
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lin Shen
Phone
010-53806898
Email
linshenpku@163.com
Facility Name
Affiliated Hospital of Hebei University
City
Baoding
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Aimin Zang
Facility Name
China-Japan Friendship Hospital
City
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Liqun Jia
Facility Name
Luhe Hospital Affiliated to Capital Medical University
City
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dong Yan
Facility Name
Peking University People's Hospital
City
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yingjiang Ye
Facility Name
Jilin Provincial Tumor Hospital
City
Changchun
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ying Cheng
Facility Name
Xiangya Hospital of Central South University
City
Changsha
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shan Zeng
Facility Name
Affiliated Hospital of Chengde Medical College
City
Chengde
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Qingshan Li
Facility Name
Three Gorges Hospital Affiliated to Chongqing University
City
Chongqing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jun Zhang
Facility Name
Fujian Cancer Hospital
City
Fuzhou
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nanfeng Fan
Facility Name
Guangdong Provincial People's Hospital
City
Guangzhou
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dong Ma
Facility Name
Southern Hospital of Southern Medical University
City
Guangzhou
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Min Shi
Facility Name
The First Affiliated Hospital of Sun Yat-sen University
City
Guangzhou
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shirong Cai
Facility Name
The Sixth Affiliated Hospital of Sun Yat-sen University
City
Guangzhou
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yanhong Deng
Facility Name
First Affiliated Hospital of Zhejiang University School of Medicine
City
Hangzhou
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nong Xu
Facility Name
Second Affiliated Hospital of Zhejiang University School of Medicine
City
Hangzhou
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fuming Qiu
Facility Name
Zhejiang Cancer Hospital
City
Hangzhou
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jie'er Ying
Facility Name
The Affiliated Tumor Hospital of Harbin Medical University
City
Harbin
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yuxian Bai
Facility Name
Anhui Cancer Hospital
City
Hefei
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yifu He
Facility Name
Anhui Provincial Hospital
City
Hefei
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yueyin Pan
Facility Name
Jinan Central Hospital
City
Jinan
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Meili Sun
Facility Name
Shandong Cancer Hospital
City
Jinan
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Changzheng Li
Facility Name
Affiliated Hospital of Jining Medical College
City
Jining
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lei Han
Facility Name
The First People's Hospital of Jining City
City
Jining
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ning Liu
Facility Name
Lanzhou University Second Hospital
City
Lanzhou
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hao Chen
Facility Name
Linyi Tumor Hospital
City
Linyi
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhen Li
Facility Name
Drum Tower Hospital Affiliated to Nanjing University School of Medicine
City
Nanjing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jia Wei
Facility Name
Jiangsu Cancer Hospital
City
Nanjing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jianwei Lu
Facility Name
The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital)
City
Nanjing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yongqian Shu
Facility Name
Qingdao University Hospital
City
Qingdao
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wensheng Qiu
Facility Name
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
City
Shanghai
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jun Zhang
Facility Name
Shanghai Changhai Hospital
City
Shanghai
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xianbao Zhan
Facility Name
Zhongshan Hospital Affiliated to Fudan University
City
Shanghai
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tianshu Liu
Facility Name
Cancer Hospital Affiliated to Shantou University Medical College
City
Shantou
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yi Jiang
Facility Name
Liaoning Cancer Hospital
City
Shenyang
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jingdong Zhang
Facility Name
Shenzhen People's Hospital
City
Shenzhen
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ruilian Xu
Facility Name
The First Affiliated Hospital of Soochow University
City
Suzhou
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kai Chen
Facility Name
Shanxi Cancer Hospital
City
Taiyuan
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mudan Yang
Facility Name
Tianjin Cancer Hospital
City
Tianjin
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yi Ba
Facility Name
Weifang People's Hospital
City
Weifang
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Guohua Yu
Facility Name
Weihai Municipal Hospital
City
Weihai
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Airong Wang
Facility Name
Huazhong University of Science Tongji Hospital, Tongji Medical College
City
Wuhan
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xianglin Yuan
Facility Name
The First Affiliated Hospital of Xi'an Jiaotong University
City
Xi'an
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Enxiao Li
Facility Name
The First Affiliated Hospital of Xiamen University
City
Xiamen
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jiayi Li
Facility Name
Affiliated Hospital of Qinghai University
City
Xining
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Junhui Zhao
Facility Name
Qinghai Provincial People's Hospital
City
Xining
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yujuan Qi
Facility Name
The First Affiliated Hospital of Xinxiang Medical College
City
Xinxiang
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Liuzhong Yang
Facility Name
Affiliated Hospital of Xuzhou Medical University
City
Xuzhou
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chao gao
Facility Name
Xuzhou Central Hospital
City
Xuzhou
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yuan Yuan
Facility Name
Subei People's Hospital of Jiangsu Province
City
Yangzhou
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xizhi Zhang
Facility Name
Yantai Yuhuangding Hospital
City
Yantai
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Liangming Zhang
Facility Name
Henan Cancer Hospital
City
Zhengzhou
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Suxia Luo

12. IPD Sharing Statement

Learn more about this trial

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

We'll reach out to this number within 24 hrs